Abstract: An absorption cycle apparatus including a working fluid is presented. The working fluid includes a metal halide, water and a zwitterion additive, wherein the zwitterion additive includes an amino acid, 2,2?-[(phosphonomethyl)imino]diaceticacid, 3-[(2-hydroxyethyl)amino]-1-propanesulfonic acid, or combinations thereof. A method of controlling crystallization in a working fluid of an absorption cycle apparatus is also presented.

Abstract: An absorbent composition includes an amino-siloxane having structure (I): wherein R1 is independently at each occurrence a C1-C6 aliphatic or aromatic radical; R2 is independently at each occurrence a C2-C10 aliphatic or aromatic radical; R3 is independently at each occurrence a hydrogen atom or a C1-C6 aliphatic or aromatic radical; R4 is independently at each occurrence a C1-C18 aliphatic or aromatic radical or R5, wherein R5 comprises structure (II): wherein X is independently at each occurrence an oxygen atom or a sulfur atom; w is between 0 and 5; y is between 0 and 10; and z is between 0 and 10; wherein, when R4 is R5 comprising the structure (II), a sum of w, y, and z is greater than or equal to 0, and, when R4 is not R5, a sum of w, y, and z is greater than or equal to 1.

Abstract: An absorption cycle apparatus including a working fluid is presented. The working fluid includes a metal halide, water and a zwitterion additive, wherein the zwitterion additive includes an amino acid, 2,2?-[(phosphonomethyl)imino]diaceticacid, 3-[(2-hydroxyethyl)amino]-1-propanesulfonic acid, or combinations thereof. A method of controlling crystallization in a working fluid of an absorption cycle apparatus is also presented.

Abstract: An absorbent composition includes an amino-siloxane having structure (I): wherein R is independently at each occurrence a C1-C6 aliphatic or aromatic radical; R2 is independently at each occurrence a C2-C10 aliphatic or aromatic radical; R3 is independently at each occurrence a hydrogen atom or a C1-C6 aliphatic or aromatic radical; R4 is independently at each occurrence a C1-C18 aliphatic or aromatic radical or R5, wherein R5 comprises structure (II): wherein X is independently at each occurrence an oxygen atom or a sulfur atom; w is between 0 and 5; y is between 0 and 10; and z is between 0 and 10; wherein, when R4 is R5 comprising the structure (II), a sum of w, y, and z is greater than or equal to 0, and, when R4 is not R5, a sum of w, y, and z is greater than or equal to 1.

Abstract: The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.

Abstract: The present invention provide Imidazole Carboxamide Compounds of Formula (I): wherein D, T, R1, R2, R3, and R6 are as defined herein, and pharmaceutically acceptable salts of such Imidazole Carboxamide Compounds. The Imidazole Carboxamide Compounds are useful in the treatment of cancer and other aberrant conditions that result from overstimulation of the PDK-1 signaling pathway.

Abstract: The instant invention provides for compounds that inhibit PDK1 activity. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting PDK1 activity by administering the compound to a patient in need of treatment of cancer.